 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALLO-501A / Allogene Therap
Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-Cell Lymphoma (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6288;
P1/2
We identified 11 patients with relapsed/refractory large B-cell lymphoma treated on the ALPHA-2 phase 1 trial (NCT04416984) with ALLO-501A, a healthy donor-derived CD19 CAR T with T cell receptor (TCR) knockout...We revealed the impact of recipient alloreactive CD8 + T cells in allogeneic CAR T rejection and identified expansion of identical allogeneic CAR T clonotypes with retained clonal hierarchy in multiple patients. While patient factors such as tumor burden and target antigen expression likely play a role as well, our results suggest that strategies to eliminate alloreactive recipient cells and enhance allogeneic CAR T fitness through improved product design, manufacturing and lymphodepletion could improve allogeneic CAR T expansion, persistence and efficacy.
- ALLO-647 / Allogene Therap, ALLO-501 / Allogene Therap
ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2530;
P1, P1/2
While patient factors such as tumor burden and target antigen expression likely play a role as well, our results suggest that strategies to eliminate alloreactive recipient cells and enhance allogeneic CAR T fitness through improved product design, manufacturing and lymphodepletion could improve allogeneic CAR T expansion, persistence and efficacy. Updated phase 1 data for ALLO-501 (ALPHA; NCT03939026) and ALLO-501A (ALPHA2; NCT04416984) showed that administration of anti-CD19 allogeneic CAR T product following use of lymphodepletion that includes ALLO-647 plus fludarabine and cyclophosphamide provided durable responses and an acceptable safety profile in CAR T-cell
- ALLO-501 / Allogene Therap
DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1418;
P1, P1/2
Conditioning with a regimen of fludarabine (F)/cyclophosphamide (C)/ALLO-647 (A, a humanized anti-CD52 monoclonal IgG1) targets host CD52+ immune cells for elimination while allowing subsequently infused CD52-knock-out ALLO-501/501A cells to persist. A single dose of AlloCAR T therapy following FCA90 conditioning provided durable responses with a manageablesafety profile in autologous CAR T-na
- ALLO-501 / Allogene Therap
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). (On Demand | S100bc; Poster Bd # 359) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2445;
P1, P1/2
A single dose of AlloCAR T therapy following FCA90 conditioning provided durable responses with a manageablesafety profile in autologous CAR T-na In these two multicenter, single-arm, open-label, phase 1 trials, a cohort of autologous CAR T-na
- ||| ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
Enrollment open, CAR T-Cell Therapy: EXPAND: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (clinicaltrials.gov) - Apr 13, 2023
P2, N=70, Recruiting, Sponsor: Allogene Therapeutics
In these two multicenter, single-arm, open-label, phase 1 trials, a cohort of autologous CAR T-na Not yet recruiting --> Recruiting
- ||| ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy: ALPHA-2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (clinicaltrials.gov) - Feb 9, 2023
P1/2, N=160, Recruiting, Sponsor: Allogene Therapeutics
Not yet recruiting --> Recruiting N=60 --> 160 | Trial completion date: Dec 2022 --> May 2029 | Trial primary completion date: Dec 2022 --> Jan 2025
- |||| ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
New P2 trial, CAR T-Cell Therapy: EXPAND: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (clinicaltrials.gov) - Feb 6, 2023
P2, N=70, Not yet recruiting, Sponsor: Allogene Therapeutics
- ||| ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
Enrollment open, Enrollment change, CAR T-Cell Therapy: ALPHA-2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (clinicaltrials.gov) - Apr 8, 2022
P1/2, N=60, Recruiting, Sponsor: Allogene Therapeutics
N=60 --> 160 | Trial completion date: Dec 2022 --> May 2029 | Trial primary completion date: Dec 2022 --> Jan 2025 Active, not recruiting --> Recruiting | N=30 --> 60
- ||| ALLO-501A / Allogene Therap, Servier
Why the precipitous drop in CR for ALLO-501A? Too much c? (Twitter) - Dec 13, 2021
- ALLO-501A / Allogene Therap, Servier
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing (GWCC - Sidney Marcus Auditorium, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2112;
P1/2
Updated efficacy and follow-up will be presented at the meeting. Currently, an ALLO-501A Phase 2 trial is planned.
- | ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
Enrollment closed, CAR T-Cell Therapy: ALPHA-2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (clinicaltrials.gov) - Oct 14, 2021
P1/2, N=30, Active, not recruiting, Sponsor: Allogene Therapeutics
Currently, an ALLO-501A Phase 2 trial is planned. Recruiting --> Active, not recruiting
- || ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therap, Servier
$ALLO #ASCO21 Ph1 ALLO-501 & ALLO-501A in R/R NHL ORR: 75% (Twitter) - Jun 4, 2021
- |||| ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therap, Servier
"Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021" https://t.co/pIdsCnMdOU (Twitter) - May 19, 2021
- ||| ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
Enrollment change, CAR T-Cell Therapy: ALPHA-2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (clinicaltrials.gov) - May 12, 2021
P1/2, N=30, Recruiting, Sponsor: Allogene Therapeutics
Recruiting --> Active, not recruiting N=120 --> 30
- ALLO-647 / Allogene Therap, ALLO-501A / Allogene Therap, Servier
[VIRTUAL] First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2587;
P1/2
Preliminary data suggest an acceptable safety profile following ALLO-501A and ALLO-647 and early signs of efficacy in LBCL . Enrollment into the consolidation cohort is ongoing; updated clinical/biomarker data of resistance and clinical activity will be presented.
- | ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therap, Servier
Allogene going to disclose anti-CAR antibodies at #ASCO21 for ALLO-501...not optimistic on this being a positive thing. (Twitter) - Feb 25, 2021
- | ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therap, Servier
Damn, I didn't remember ALLO-501 was also going up to 300+ 10e6 CAR+ cells. (Twitter) - Oct 21, 2020
- |||| ALLO-647 / Allogene Therap, cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
New P1/2 trial, CAR T-Cell Therapy: ALPHA-2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (clinicaltrials.gov) - Jun 3, 2020
P1/2, N=120, Recruiting, Sponsor: Allogene Therapeutics
- |||| ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therapeutics, Servier
Clinical: Partial Responses are NOT real responses, they are not durable it buys maybe 2-4 months of time...CRs in DLBCL are the only real responses. ALLO501+ALLO647 showed higher CR rate, the secret sauce is the conditioning more than the cells, thus far with allo-CAR-T (Twitter) - Jun 1, 2020
- |||| ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therapeutics, Servier
Clinical, CAR T-Cell Therapy: They show much promise but the future should tell their long term efficacy especially when compared to CAR T cells. The ALLO-501 study showed promising results but sample size is very small and little long-term follow-up. Nonetheless, the future of oncology is exciting. (Twitter) - May 30, 2020
- ||||| ALLO-501 / Allogene Therap, Servier, ALLO-501A / Allogene Therapeutics, Servier
Clinical: Very encouraging early results with ALLO-501 "off the shelf" CAR T. A bit complicated process with knocking out 2 genes and introducing a CD19 and CD20 binding proteins. No GVHD, 50% infection. 50% CR rate in 8 adequately treated pts. To be watched as more pts are treated (Twitter) - May 30, 2020
- ||| ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier
First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. Only 9 pos treated, ORR 78% with manageable toxicity, with no GVHD. Too early to determine durability of responses https://t.co/qierxsOm5R (Twitter) - May 28, 2020
- || ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier
#RT @cells_nnm: @SimonBornschein @JacobPlieth @OSmithBio @GruppSteve No, my understanding is ALLO-501A is done and ready to go for abbreviated Ph1 and further to pivotal and commercial (Twitter) - May 14, 2020
- || ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier
No, my understanding is ALLO-501A is done and ready to go for abbreviated Ph1 and further to pivotal and commercial (Twitter) - May 14, 2020
- |||| ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier
P1 data: This was touched on in March, the switch was removed due to it restricting use in NHL. At the time the intention was for Allo-501a to enter clinic in H2 2020, potentially with an abbreviated phase 1. (Twitter) - May 14, 2020
- |||| ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Clinical: #RT @cells_nnm: $ALLO first data release in NHL - coverage with CEO's and @GruppSteve commentary https://t.co/5m5gHv2g2M company disclosed a difference between ALLO-501 and ALLO-501A. The latter won't have a Rituxan-induced safety switch. Will ALLO-501 be shelved soon after ASC… (Twitter) - May 13, 2020
- |||| ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Clinical: $ALLO first data release in NHL - coverage with CEO's and @GruppSteve commentary https://t.co/DCyEqghC7p company disclosed a difference between ALLO-501 and ALLO-501A. The latter won't have a Rituxan-induced safety switch. Will ALLO-501 be shelved soon after ASCO? @JacobPlieth (Twitter) - May 13, 2020
- |||| ALLO-501 / Allogene Therapeutics, Servier, ALLO-501A / Allogene Therapeutics, Servier
Clinical: #ASCO20 $ALLO ALLO-501 n=12 (9 received ALLO-501, 3 DL at 4:4:1) Ph1 study in adults w/R/R LBCL/FL No DLTs or GvHD ORR: 72% (3 CR 4 PR) mFollow Up: 2.7m Gotta love @Arie_Belldegrun (Twitter) - May 13, 2020
- Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2115;
P1
ALLO-647 may be an effective and selective lymphodepleting agent with CD52 gene editing, and ALLO-501 shows evidence of clinical activity in pts with advanced NHL. Enrollment is ongoing, and updated safety, efficacy, PK/PD data will be presented including pts treated with increasing doses of ALLO-647.